Pharmacologic actions of the second-generation leukotriene B4 receptor antagonist LY293111: In vitro studies

Journal of Pharmacology and Experimental Therapeutics

Volumn 288, Issue 1, 1999, Pages 286-294

  Jackson, William T ^c   Froelich, Larry L ^c   Boyd, Robert J ^c   Schrementi, James P ^c   Saussy Jr , David L ^a,c   Schultz, Richard M ^c   Sawyer, J Scott ^c   Sofia, Michael J ^b,c   Herron, David K ^c   Goodson Jr , Theodore ^c   Snyder, David W ^c   Pechous, Penni A ^c   Spaethe, Stephen M ^c   Roman, Carlos R ^c   Fleisch, Jerome H ^c  

^a GLAXOSMITHKLINE   (United States)

^b Intercardia Research Laboratories   (United States)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [2 PROPYL 3 [3 [2 ETHYL 4 (4 FLUOROPHENYL) 5 HYDROXYPHENOXY]PROPOXY]PHENOXY]BENZOIC ACID; 5 ETHYL 2 HYDROXY 4 [6 METHYL 6 (1H TETRAZOL 5 YL)HEPTYLOXY]ACETOPHENONE; 7 [3 (4 ACETYL 3 METHOXY 2 PROPYLPHENOXY)PROPOXY] 3,4 DIHYDRO 8 PROPYL 2H 1 BENZOPYRAN 2 CARBOXYLIC ACID; CALCIMYCIN; FORMYLMETHIONYLLEUCYLPHENYLALANINE; LEUKOTRIENE B4 RECEPTOR ANTAGONIST; LIPID; THROMBIN;

ARTICLE; CHEMOLUMINESCENCE; CONCENTRATION RESPONSE; DRUG POTENCY; DRUG RECEPTOR BINDING; GUINEA PIG; HUMAN; HUMAN CELL; LIPID METABOLISM; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

EID: 0032909952     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. 4. Clin Biochem 23:459-468.
2. Borgeat P and Samuelsson B (1979) Transformation of arachidonic acid by rabbit polymorphonuclear leukocytes: Formation of a novel dihydroxyeicosatetraenoic acid. J Biol Chem 254:2643-2646.
3. Brooks CDW and Summers JB (1996) Modulators of leukotriene biosynthesis and receptor activation. J Med Chem 39:2629-2654.
4. Cho HL, Ho PPK, Mihelich ED, Spaethe SM, Hite GA, Pechous PA, Suarez T and Snyder DW (1993) LY280810, a novel 5-lipoxygenase inhibitor: In vitro pharmacology relative to zileuton. Pharmacologist 35:196.
5. 4 receptor. Receptor 2:169-179.
6. 50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
7. 4 receptor antagonist. J Med Chem 36:2703-2705.
8. Drazen JM and Schneider MW (1978) Comparative responses of tracheal spirals and parenchymal strips to histamine and carbachol in vitro. J Clin Invest 61:1441-1447.
9. 4 in inflammation. Crit Rev Immunol 10:1-12.
10. 4- and 12(R)-HETE-mediated events. Inflammation 19:193-205.
11. 4 antagonists. Seventh International Conference of the Inflammation Research Association, White Haven, PA, Abstract P29.
12. 4. 1. Structure-activity relationships of the benzophenone nucleus. J Med Chem 33:2798-2807.
13. 4. 2. Structure-activity relationships of the lipophilic side chain. J Med Chem 33:2807-2813.
14. 4: Identification of a subset of high affinity receptors that transduce the chemotactic response. J Exp Med 159:1027-1041.
15. 4 receptor antagonists: The LY255283 series of hydroxyacetophenones. J Med Chem 35: 1818-1828.
16. 4-induced neutrophil activation by LY223982. J Pharmacol Exp Ther 263:1009-1014.
17. 4 receptor antagonists. J Med Chem 36:1726-1734.
18. Jackson WT and Fleisch JH (1996) Development of novel anti-inflammatory agents: A pharmacological perspective on leukotrienes and their receptors. Prog Drug Res 46:115-168.
19. 4-induced neutrophil functions. Prostaglandins 44:261-275.
20. 4 antagonist with oral activity in the murine collagen-induced arthritis model. J Med Chem 37:3197-3199.
21. Lewis RA, Austen KF and Soberman RJ (1990) Leukotrienes and other products of the 5-lipoxygenase pathway: Biochemistry and relation to pathobiology in human diseases. N Engl J Med 323:645-655.
22. 4 receptor antagonists (LY255283 and SC-41930) on calcium mobilization and integrin expression of activated human neutrophils. Prostaglandins Leukot Essent Fatty Acids 46:265-270.
23. 4 receptor antagonist. Biochem Pharmacol 49:1683-1690.
24. 4 receptor antagonist. Br J Clin Pharmacol 42:457-464.
25. 4 antagonists as potential therapeutic agents (Roland D). Inflamm Res Assoc Newsletter 3:3.
26. Rajkovic IA and Williams R (1985) Rapid microassays of phagocytosis, bacterial killing, superoxide and hydrogen peroxide production by human neutrophils in vitro. J Immunol Methods 78:35-47.
27. 4 antagonists in the mouse ear edema and rat neutropenia models. Inflamm Res 44 (Suppl 2):S141-S142.
28. 4 receptor antagonist demonstrating potent antiinflammatory activity. Adv Prostaglandin Thromboxane Res 23:275-277.
29. 2 receptor in guinea pig lung membranes using a radioiodinated thromboxane mimetic. Mol Pharmacol 39:72-78.
30. 4 receptor antagonists: Recent clinical developments. Exp Opin Invest Drugs 5:73-77.
31. 4 receptor antagonist. J Med Chem 38:4411-4432.
32. 4-induced human neutrophil adhesion and superoxide production. Prostaglandins Leukot Essent Fatty Acids 43:267-271.
33. 4 receptor antagonist CP-105696. J Pharmacol Exp Ther 273:176-184.
34. 4 receptor antagonist. Eur J Pharmacol 223:57-64.
35. 4. Pharmacology (Basel) 31:225-236.
36. Spaethe SM, Snyder DW, Pechous PA, Clarke T and VanAlstyne EL (1992) Guinea pig whole blood 5-lipoxygenase assay: Utility in the assessment of potential 5-lipoxygenase inhibitors. Biochem Pharmacol 43:377-382.
37. Stenson WF (1990) Role of eicosanoids as mediators of inflammation in inflammatory bowel disease. Scand J Gastroenterol 172 (Suppl):13-18.
38. 4 receptors. J Pharmacol Exp Ther 268:1499-1505.
39. 4 receptor antagonist (LY293111). Biochem Pharmacol 53:1005-1012.
40. van Rossum JM (1963) Cumulative dose-response curves. II. Technique for the making of dose-response curves in isolated organs and the evaluation of drug parameters. Arch Int Pharmacodyn Ther 143:299-330.